Medical Disclaimer
RxCompareHub editorial content is informational and educational, not medical advice. Compounded medications discussed are NOT FDA-approved and are NOT the same as brand-name FDA-approved alternatives.
Editorial information only
RxCompareHub editorial content is for informational and educational purposes only. It is not medical advice and does not substitute for consultation with a licensed physician.
Compounded GLP-1 medications
Compounded semaglutide and compounded tirzepatide referenced on this site are NOT FDA-approved. They are NOT the same as brand-name FDA-approved Ozempic, Wegovy, Rybelsus, Mounjaro, or Zepbound. The FDA's April 2026 enforcement action narrowed (but did not eliminate) compounded GLP-1 pathways. Compounded medications dispensed by licensed 503A or 503B pharmacies under valid prescriptions remain available.
Peptide therapy
Most peptides referenced on this site (BPC-157, CJC-1295, Ipamorelin, GHK-Cu, TB-500, PT-141 for off-label use, NAD+, etc.) are not FDA-approved. They are compounded under prescription by licensed pharmacies and used off-label under physician oversight. Use any peptide therapy only under licensed physician supervision.
Boxed warnings
Semaglutide and tirzepatide carry boxed warnings for risk of thyroid C-cell tumors (rodent finding; not observed in human cohorts). Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC), MEN 2 syndrome, or pregnancy/breastfeeding. Always discuss contraindications with your physician.
No physician-patient relationship
Reading RxCompareHub does not establish a physician-patient relationship. Editorial content cannot substitute for in-person or properly-supervised telehealth evaluation.
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →